Results 121 to 130 of about 80,955 (206)

Enhancing PARP inhibitor efficacy in ovarian cancer: targeting the PI3K/AKT/mTOR pathway. [PDF]

J Ovarian Res
Wang Y, Xia Q, Wang X, Lu Y, Wang S, Jiao Y.   +5 more
europepmc   +1 more source

Challenges in employing overall survival as a primary outcome in ovarian cancer studies: insights from PARP inhibitor trials. [PDF]

Front Oncol
Siegler Y, Matanes E.
europepmc   +1 more source

Tumor cell-derived IFN spatially reprograms osteopontin-enriched macrophage niches to promote PARP inhibitor resistance. [PDF]

J Clin Invest
Liu D, Tao K, Xu C, Yang W, Cai C, Feng C, Xiong K, Wu S, Lin Y, Peng Z, Chi J, Pan W, Zhong Q, Liu J, Li X, Liu X, Zhou D, Ma D, Zhao GN, Xia Y, Fang Y, Gao Q.   +21 more
europepmc   +1 more source

Case Report: Use of mirvetuximab soravtansine in a patient with platinum-resistant ovarian cancer and concomitant PARP-inhibitor-related myelodysplastic syndrome. [PDF]

Front Oncol
Njonou Noujiep SS, Altmann J, Bullinger L, Sehouli J.   +3 more
europepmc   +1 more source

Exploring the optimal cutoff point and genomic characteristics for PARP inhibitor maintenance therapy in early recurrence of ovarian cancer. [PDF]

J Ovarian Res
Ye L, Chen Y, Chen Y, Zhao Q, Cheng X, Wang X, Xu X, Guo W, Chen X, Ni J.   +9 more
europepmc   +1 more source

Impairment of oxidative metabolism compromises Rad51 recruitment and potentiates PARP inhibitor effectiveness in ovarian cancer. [PDF]

J Exp Clin Cancer Res
Formenti L, Abramo F, Dellavedova G, Dematteis V, Decio A, Grasselli C, Fabbrizio P, Brunelli L, Giavazzi R, Ghilardi C.   +9 more
europepmc   +1 more source

Novel therapeutic potential of the PARP inhibitor talazoparib in synovial sarcoma and its combined effect with ATR inhibitor. [PDF]

Discov Oncol
Honda N, Taniguchi H, Ono S, Hayashi F, Imamura E, Gyotoku H, Takemoto S, Takazono T, Ishimoto H, Sakamoto N, Obase Y, Masutani M, Nishino T, Mukae H.   +13 more
europepmc   +1 more source

Clinical approaches to overcome PARP inhibitor resistance. [PDF]

Mol Cancer
Zou Y, Zhang H, Chen P, Tang J, Yang S, Nicot C, Guan Z, Li X, Tang H.   +8 more
europepmc   +1 more source

Replication protein A protects lagging strand gaps, restricting PARP inhibitor-induced synthetic lethality in BRCA1-deficient tumors. [PDF]

Nucleic Acids Res
VanderVere-Carozza PS, Jordan MR, Garrett JE, Pollok KE, Pawelczak KS, Turchi JJ.   +5 more
europepmc   +1 more source

The mitochondrial translocation of phosphorylated EZH2 promotes PARP inhibitor resistance in BRCA1-deficient epithelial ovarian cancer. [PDF]

Cell Discov
Hu L, Ma X, Cai X, Yan T, Zhou K, Shan C, Guo N, Zheng H, Wang Y, Tong Y, Xie S, Zhang H, Chen C, Gong Z, Guo L, Lu R.   +15 more
europepmc   +1 more source